DK0980383T3 - Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener - Google Patents
Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogenerInfo
- Publication number
- DK0980383T3 DK0980383T3 DK98918801T DK98918801T DK0980383T3 DK 0980383 T3 DK0980383 T3 DK 0980383T3 DK 98918801 T DK98918801 T DK 98918801T DK 98918801 T DK98918801 T DK 98918801T DK 0980383 T3 DK0980383 T3 DK 0980383T3
- Authority
- DK
- Denmark
- Prior art keywords
- oestr
- estrogens
- hydroxy
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85056897A | 1997-05-02 | 1997-05-02 | |
PCT/US1998/008481 WO1998050413A1 (en) | 1997-05-02 | 1998-04-28 | Pharmaceutically acceptable salts of 3-hydroxy-estr-5(10)-en-17-one 3-sulphate active as estrogens |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0980383T3 true DK0980383T3 (da) | 2003-04-14 |
Family
ID=25308509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98918801T DK0980383T3 (da) | 1997-05-02 | 1998-04-28 | Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0980383B1 (da) |
JP (1) | JP2001523266A (da) |
KR (1) | KR20010012193A (da) |
CN (1) | CN1254341A (da) |
AR (1) | AR015375A1 (da) |
AT (1) | ATE230413T1 (da) |
AU (1) | AU730300B2 (da) |
BR (1) | BR9809437A (da) |
CA (1) | CA2289008A1 (da) |
DE (1) | DE69810461T2 (da) |
DK (1) | DK0980383T3 (da) |
ES (1) | ES2187963T3 (da) |
HK (1) | HK1025336A1 (da) |
WO (1) | WO1998050413A1 (da) |
ZA (1) | ZA983698B (da) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL364675A1 (en) * | 2001-03-16 | 2004-12-13 | Wyeth | Estrogen replacement therapy |
-
1998
- 1998-04-28 DE DE69810461T patent/DE69810461T2/de not_active Expired - Fee Related
- 1998-04-28 KR KR19997010142A patent/KR20010012193A/ko not_active Application Discontinuation
- 1998-04-28 AU AU71655/98A patent/AU730300B2/en not_active Ceased
- 1998-04-28 EP EP98918801A patent/EP0980383B1/en not_active Expired - Lifetime
- 1998-04-28 CA CA002289008A patent/CA2289008A1/en not_active Abandoned
- 1998-04-28 AT AT98918801T patent/ATE230413T1/de not_active IP Right Cessation
- 1998-04-28 ES ES98918801T patent/ES2187963T3/es not_active Expired - Lifetime
- 1998-04-28 WO PCT/US1998/008481 patent/WO1998050413A1/en not_active Application Discontinuation
- 1998-04-28 CN CN98804720A patent/CN1254341A/zh active Pending
- 1998-04-28 JP JP54815998A patent/JP2001523266A/ja active Pending
- 1998-04-28 BR BR9809437-8A patent/BR9809437A/pt not_active IP Right Cessation
- 1998-04-28 DK DK98918801T patent/DK0980383T3/da active
- 1998-04-30 AR ARP980102024A patent/AR015375A1/es unknown
- 1998-04-30 ZA ZA9803698A patent/ZA983698B/xx unknown
-
2000
- 2000-07-24 HK HK00104555A patent/HK1025336A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0980383A1 (en) | 2000-02-23 |
CA2289008A1 (en) | 1998-11-12 |
EP0980383B1 (en) | 2003-01-02 |
ES2187963T3 (es) | 2003-06-16 |
HK1025336A1 (en) | 2000-11-10 |
KR20010012193A (ko) | 2001-02-15 |
BR9809437A (pt) | 2000-06-13 |
DE69810461T2 (de) | 2003-10-02 |
JP2001523266A (ja) | 2001-11-20 |
ZA983698B (en) | 1999-11-01 |
AR015375A1 (es) | 2001-05-02 |
ATE230413T1 (de) | 2003-01-15 |
AU7165598A (en) | 1998-11-27 |
CN1254341A (zh) | 2000-05-24 |
AU730300B2 (en) | 2001-03-01 |
WO1998050413A1 (en) | 1998-11-12 |
DE69810461D1 (de) | 2003-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL300952I2 (nl) | Peramivir en farmaceutisch aanvaardbare zouten daarvan | |
DK1218374T3 (da) | Farmaceutisk aktive sulfonamidderivater | |
NO20010556L (no) | Fremgangsmate for oftalmisk administrering | |
PT1220856E (pt) | Compostos farmaceuticamente activos | |
ATE284385T1 (de) | Sulfonamidderivate | |
DE69514087D1 (de) | Pharmazeutisch aktive substituierte aromatische verbindungen | |
NO20005084D0 (no) | Heterosykliske glysyl <beta>-alanin derivater som vitronektinantagonister | |
IS5340A (is) | Arýloxýarýlsúlfónýlamínó hýdroxamsýru afleiður | |
NO984106D0 (no) | Azolobenzazepin-derivater som neurologisk aktive midler | |
DK1028961T3 (da) | Pleuromutilinderivater som antimikrobielle midler | |
NO20012636D0 (no) | Kontrollert frigivelsesformulering som omfatter GNRH-II | |
DK1140034T3 (da) | Formulering af divalproex-natrium med kontrolleret frigivelse | |
DK1073416T3 (da) | Anvendelse af NO som anti-inflammatorisk middel | |
DK0975623T3 (da) | Indazolamidforbindelser som sertoninerge midler | |
NO995251D0 (no) | FremgangsmÕte for administrering av haloterapi | |
PT868911E (pt) | Formulacoes de rapamicina para administracao oral | |
NO972887D0 (no) | Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel | |
FI972103A0 (fi) | Fluorokinolonin uusi fysikaalisesti stabiili kiinteä muoto | |
DK0941097T3 (da) | Anvendelse af aktivstofblandinger til fremstilling af hypocholesterolæmiske midler | |
DE69528843D1 (de) | Pharmakologisch aktive 2-mercaptobenzimidazolderivate | |
DK1075471T3 (da) | Idolylderivater som serotonerge midler | |
DK0980383T3 (da) | Farmaceutisk acceptable salte af 3-hydroxy-østr-5(10)-en-17-on-3-sulfat aktive som østrogener | |
NO20011402D0 (no) | Tricykliske <delta>3-piperidiner som farmasøytiske midler | |
NO995821L (no) | Anvendelse av 4-substituerte tetrahydropyridiner for fremstilling av medisiner som virker på TGF-<beta>1 | |
NO972905D0 (no) | Tienoksasinon-derivater anvendelige som antivirusmidler |